Cellyan Biotechnology Co., Ltd has been granted an additional 180-day grace period by Nasdaq to regain compliance with the minimum $1.00 closing bid price requirement. The company received a notification letter on July 14, 2026, extending the deadline to January 11, 2027. To meet the requirement, Cellyan's Class A ordinary shares must close at or above $1.00 for at least ten consecutive business days before that date. The company stated it will coordinate feasible compliance solutions, including a possible reverse share split, though there is no assurance of success. The notification has no immediate effect on the listing, and shares continue to trade under the ticker HKPD.
Hong Kong Pharma Digital Technology Holdings Limited Ordinary sharesNasdaq granted extension to regain minimum bid price compliance, avoiding immediate delisting.